Sun Pharmaceutical Industries Ltd
NSE: SUNPHARMA BSE: 524715
₹1748
-10 (0.57%)
Wed, 28 Oct 2026, 05:34 pm
Market Cap (in Cr)418194.25
PE Ratio34.67
Dividend0.92
Health Technology
Pharmaceuticals: Major
24.5KSun Pharmaceutical Industries Ltd Company History
1983
- Incorporated as partnership firm by Dilip Sanghvi and family in Vapi, Gujarat.
- Converted to public limited company effective March 1.
1994
- Commissioned bulk drug plant at Panoli.
- Commissioned second formulation plant at Silvassa in April.
- Enhanced bulk drugs capacity at Panoli to 92,000 Kgs p.a.
- Enhanced formulation capacity to 1,800 million tablets p.a.
- Proposed modernization of Vapi formulation unit to 1,440 million tablets p.a.
- Proposed additional facilities at SPARC R&D centre.
- Issued 71,85,000 equity shares to promoters.
1995
- Introduced Clofranil SR and Syndopa CR.
- Entered MOU with Knoll Pharmaceuticals for Ahmednagar unit.
- Allotted 35,92,500 bonus shares in 1:2 ratio.
- Issued 3,23,400 rights shares at premium of Rs 130.
- Issued 37,00,300 equity shares at premium of Rs 140 to public.
1996
- Launched 18 new products and 4 line extensions.
- Acquired controlling stake in MJ Pharmaceuticals.
- Signed MoU with Shah family for MJPL shareholding.
1997
- Acquired 78,36,000 equity shares.
- Merged Tamil Nadu Dadha Pharmaceuticals effective April 1 in 4:1 ratio.
- Allotted 4,13,633 equity shares to erstwhile TDPL shareholders.
- Approved 1:4 swap ratio for TDPL merger.
- Set up Sun Pharma Advanced Research Centre (SPARC) in Vadodara.
- Planned new tablet manufacturing facility at Silvassa.
1998
- Launched Duracard for blood pressure and cholesterol.
- Launched Cardivas for heart failure.
- Launched Muvera anti-inflammatory and Octapeptide Octride.
- Allotted 2,08,000 shares to shareholders of Milment Labs pursuant to amalgamation.
- Converted Sun Pharma Exports into 100% subsidiary.
1999
- Planned pharmaceutical plant in Bangladesh under joint venture.
- Hived off Sun Pharmaceutical Exports into 100% subsidiary.
2000
- Merged wholly owned subsidiary Sun Pharma Exports.
- Allotted 3,08,44,466 bonus equity shares in 2:1 ratio.
- Launched Edegra (Sildenafil) in 25, 50, 100 mg.
- Introduced products including Celact, Oleanz, Rofact, Nodict, Fexotrol, Zelast, Ketorid.
- Merged 99.28% subsidiary Sun Pharmaceuticals Exports.
2001
- Approved merger of Pradeep Drug Company.
- Approved merger of Sun Pharmaceutical Advanced Research Centre.
- Launched 33 new products across speciality divisions.
- Ranked 5th by domestic prescription product sales; rated among best 200 global companies by Forbes.
2002
- Caraco received US FDA preliminary approval for metformin hydrochloride.
- Shareholders approved merger with Pradeep Drug Company effective April 1, 2000.
- Made open offer to purchase shares at Rs 600 per share.
- Launched Lupride Depot IM for prostate cancer.
- Inducted Keki Mistry to board of directors.
- Allotted 18,71,77,232 6% Cumulative Redeemable Preference Shares as bonus.
2003
- Announced buyback of up to 2,000,000 equity shares.
- Accepted resignation of R K Baheti; appointed Kamlesh H Shah as Company Secretary.
- Caraco received US FDA approval for generic Digoxin.
- Redeemed 1,42,99,833 6% Cumulative Redeemable Preference Shares.
- Extinguished 3,01,20,608 Preference Shares.
- Board approved closure of share buyback.
- Delisted equity shares from Vadodara Stock Exchange.
2004
- Acquired common stock and options in Caraco, increasing stake to over 60%.
- Halol formulation site received approvals from USFDA, UK MHRA, others.
- Two API factories received USFDA approval.
- Acquired Phlox Pharma, cephalosporin actives manufacturer.
- Acquired niche brands Ortho-Est and Midrin from Women's First Healthcare.
- Ranked by Forbes Global among most valuable companies (turnover < $2 billion).
2005
- Acquired plant in Bryan, Ohio, US and ICN Hungary business from Valeant Pharma.
- Acquired intellectual property and assets of Able Labs from US bankruptcy court.
- Dilip Sanghvi received E&Y Entrepreneur of the Year award in healthcare.
- Selected by Forbes as one of best 200 companies in Asia (sales < USD 1 billion).
- Shifted registered office to SPARC, Tandalja, Vadodara.
2006
- Announced demerger of innovative business into new company.
2007
- Completed demerger of innovative business into SPARC Ltd., listed on Indian stock exchanges.
- Signed agreements to acquire Taro Pharmaceutical Industries for $454 million.
2008
- Launched generic Pantoprazole Sodium DR Tablets 40 mg in the US.
- Acquired 100% ownership of Chattem Chemicals.
2010
- Completed acquisition of controlling stake in Taro Pharmaceutical Industries.
- Won court victory in battle to acquire Taro Pharmaceuticals.
- Launched generic Exelon in US.
- Supreme Court of Israel ruled in favor of Sun Pharma.
- Split face value of shares from Rs 5 to Re 1.
2011
- Established joint venture with Merck & Co. to develop and commercialize novel formulations in emerging markets.
- Entered strategic partnership with MSD in India to co-market diabetes drug.
2012
- Received USFDA approval for generic Zyprexa.
- Israel Makov appointed Chairman of Sun Pharma Board.
- Acquired URL generic business from Takeda.
- Promoters emerged as new JV partner for Telenor operations in India.
2013
- Received US FDA approval for generic Cymbalta.
- Formed joint venture with Intrexon for therapeutics for ocular diseases.
- Received USFDA approval for generic Prevacid.
- Received USFDA approval for generic Depo-Testosterone Injection.
- Announced 1:1 bonus issue.
- Received tentative USFDA approval for generic Januvia and Glumetza.
- Received USFDA approval for generic Doxil.
2014
- Received US FDA approval for generic Temodar.
- Acquired Pharmalucence.
- Entered licensing agreement with Merck & Co. for Tildrakizumab.
- Announced acquisition of Ranbaxy for US$4 billion.
2015
- Received US FTC clearance for Ranbaxy acquisition.
- Entered distribution agreement with AstraZeneca for ticagrelor in India.
- SPARC licensed Xelpros (Latanoprost BAK-free) to Sun Pharma.
- High Court of Gujarat approved amalgamation of Sun Pharma Global Inc.
- Received US FDA approval for Ximino.
- Completed acquisition of Opiates business in Australia.
- Announced Absorica patent litigation settlement.
- Acquired Insite Vision.
2016
- Received CCI approval for CNS deal.
- Launched Imatinib Mesylate in the US.
- Acquired Novartis brands for Rs 1,900 crore.
- Received USFDA approval for BromSite.
- Signed exclusive agreement with ICGEB for novel botanical drug for Dengue.
- Launched sunscreen brand Suncros.
- Launched Gemcitabine InfuSMART in Europe.
- Received approval for generic Glumetza.
- Completed acquisition of Ocular Technologies.
- Completed acquisition of 85% stake in JSC Biosintez.
2017
- FDEC commenced roll-out of Malaria demonstration project.
- Subsidiary received approval for new label for Odomzo.
- Received EIR for Dadra formulation facility.
2018
- Launched Kapspargo Sprinkle in the US.
- Received CSR award from FGI.
2019
- Launched Drizalma Sprinkle in the US.
- Launched Ready-to-Infuse INFUGEM in the US.
2020
- Launched FluGuard (Favipiravir) in India at Rs. 35 per tablet.
- Introduced ABSORICA LD Capsules for severe recalcitrant nodular acne in the US.
2021
- Launched website for Long Term Care Portfolio in the US.
- Launched Sunkalp on National Doctors' Day.
- Launched Chericof 12 in India for 12-hour cough relief.
2022
- Entered license agreement with SPARC for commercialization of phenobarbital for injection in the US.
- Expanded license and supply agreements with Cosmo for WINLEVI to include Japan.
- Launched CEQUA, first dry eye treatment with nanomicellar technology, in Canada.
- Obtained exclusive patent license from Lundbeck to introduce Vortioxetine in India.
- Acquired Uractiv Portfolio from Fiterman Pharma in Romania.
2023
- Entered licensing agreement with Zydus for co-marketing Desidustat in India.
- US FDA accepted NDA filing for Deuruxolitinib.
- Sun Pharma Canada launched PR WINLEVI (clascoterone cream 1% w/w) for acne.
- Entered licensing agreement with Pharmazz Inc. for Tyvalzi (Sovateltide) in India.
- Launched nationwide initiative Second Birth Date on National Doctor’s Day.
2024
- Entered global exclusive commercialization, license, and supply agreement with Philogen for FIBROMUN.
- Completed acquisition of all outstanding shares of Taro.
- Included in S&P Global Sustainability Yearbook.
- Launched STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections.
